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ABSTRACT
Cordyceps (Cordyceps sinensis SACCARDO.) is a popular traditional tonic used in Taiwan and mainland China. Cyclosporin is an
important immunosuppressant with narrow therapeutic index. This study investigated the effect of coadministration of cordyceps on
cyclosporin pharmacokinetics in rats. Cyclosporin was intravenously (0.8 mg/kg) and orally (2.5 mg/kg) administered with and without
cordyceps (2.0 g/kg), respectively, in crossover designs. Blood samples were collected by cardiopuncture and quantitated by a specific
monoclonal fluorescence polarization immunoassay. Pharmacokinetic parameters of cyclosporin were calculated using noncompartment model. Paired Student’s t-test was used for statistical comparison. Our results indicated that oral coadministration of cordyceps
significantly decreased the Cmax and AUC0-540 of cyclosporin by 85.5% and 83.2%, respectively. In addition, when rats were given
cordyceps 1 hr before cyclosporin dosing, the Cmax and AUC0-540 of cyclosporin were significantly decreased by 85.9% and 84.4%,
respectively. By contrast, when cyclosporin was given as an intravenous bolus, the disposition of cyclosporin was not altered by
cordyceps, indicating that the interaction between oral cyclosporin and cordyceps occurred during the absorption phase. In conclusion,
cordyceps markedly decreased the oral bioavailability of cyclosporin. Patients treated with cyclosporin are suggested to avoid the concurrent use of cordyceps for efficacy and safety.
Key words: Cordyceps sinensis, cyclosporin, pharmacokinetics, drug interaction

INTRODUCTION
Cordyceps sinensis SACCARDO. (CS), a fungus parasitic
on the insect larvae of Lepidoptera, is an important Chinese
medicine used as a tonic in Taiwan and mainland China.
Traditional uses of CS include treatments for respiratory
diseases like asthma, bronchial and lung inflammation, cardiovascular diseases like arrhythmia and hypertension, as
well as kidney and liver diseases (1-3) . Recent studies
reported various pharmacological effects of cordyceps,
including anti-hyperglycemia(4), antioxidation(5-7), inhibition of tumors(8,9), induction of mesangial cell apoptosis(10)
and stimulation of steroidogenesis (11,12) . In addition,
cordyceps also demonstrated immunomodulatory effect(13)
and had been proven beneficial for autoimmune disease(14).
CS was reported to contain various chemical compositions including proteins, amino acids, fats, nucleosides and
carbohydrates. The amino acids in CS consist of glutamic
acid, aspartic acid, arginine and glycine(15,16). Nucleosides
in CS include adenosine and cordycepin (3’-deoxyadenosine), which have usually been assumed to be the bioactive
* Author for correspondence. Tel: +886-4-22053366 ext. 5208;
Fax: +886-4-22031028; E-mail: kcwen0520@mail.cmu.edu.tw

ingredients and indices for estimation of the CS quality(17).
Polysaccharides are one of the major active ingredients in
CS and possess various beneficial effects such as inhibition
of lipid peroxidation(5), prevention of hemolysis(6) and inhibition of tumors(7).
In oriental countries, traditional Chinese medicines
have been extensively used to prevent and cure many
diseases due to low toxicity and rare complication.
However, the hidden risks of herb - drug interactions are
generally overlooked. Cyclosporin is an important
immunosupressant with narrow therapeutic index.
Subtherapeutic blood level of cyclosporin causes allograft
rejection, whereas supratherapeutic blood level leads to
nephrotoxicity, hepatotoxicity or neurotoxicity(18). This
study investigated the effect of coadministration of
cordyceps on the pharmacokinetics of cyclosporin in rats.

MATERIALS AND METHODS
I. Chemicals
Cyclosporin (Neoral®, 100 mg/mL) was provided by
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Novartis Co. (Taiwan) and properly diluted with water to
1.25 mg/mL. Rhodamine 123 was purchased from Aldrich
(Milw. WI, USA). Medium 199 was supplied by Sigma
(St. Louis, MI, USA). Milli-Q plus water (Millipore,
Bedford, MA, USA) was used for all preparations. TDx kit
was purchased from Abbot Laboratories (Abbot Park, IL,
USA) for the quantitation of cyclosporin in blood.
II. Preparation of CS for Administration
CS was a gift from Dr. Hung-Lung Hou (Chiayi,
Taiwan) and identified by macroscopic and microscopic
examination. It was ground to fine powder and well
suspended in distilled water to 200 mg/mL.
III. Animals and Drug Administration
Male Sprague-Dawley rats (300-400 g) were fasted for
12 hr before drug administration. Cyclosporin (2.5 mg/kg)
was orally given to rats with and without an oral dose of
CS (2.0 g/kg) concomitantly just prior to cyclosporin (n =
6) and 1 hr before cyclosporin (n = 7), respectively, in
crossover designs. Both cyclosporin and CS were given via
gastric gavage. One week was allowed for washout.
In separate study, cyclosporin was intravenously given
to 8 rats (0.8 mg/kg) with and without a concomitant oral
dose of CS (2.0 g/kg) in crossover design. CS was given
via gastric gavage immediately after the intravenous bolus
of cyclosporin via tail vein. One week was allowed for
washout. The animal study adhered to “The Guidebook for
the Care and Use of Laboratory Animals (2002)”
(published by the Chinese Society for the Animal Science,
Taiwan, ROC).

ng/mL. The LLOQ (lower limit of quantification) of
cyclosporin was 25.0 ng/mL.
VI. Everted Intestine Sac Study(21)
Nine Sprague-Dawley rats were fasted for 24 hr and
then sacrificed with ether. Segments of jejunum and ileum,
each with 25 cm in length, were removed. The segments
were washed with iced saline and then everted and ligated
at both ends. Subsequently, this sac was incubated for 20
min in 50 mL of Medium 199 solution containing 0.5 g of
cordyceps, which was gassed with 95% O 2/5% CO 2 at
37˚C. Afterwards, the sac was filled with 3.0 mL of
Medium 199 solution containing 20.0 µg/mL rhodamine
123. Solutions outside the sac (800 µL each) were taken
every 20 min up to 100 min as sample. The concentration
of rhodamine 123 in each sample was determined fluorometrically using a Luminescence Spectrometer LS-50B
(Perkin Elmer, USA).
VII. Data Analysis
The area under the serum concentration - time curves
(AUC0-540) of oral and intravenous cyclosporin were calculated using noncompartment models of WINNONLIN
(version 1.1, SCI software, Statistical Consulting, Inc.,
Apex, NC, USA), respectively. The peak serum concentration (Cmax) and the time to peak concentration (Tmax) were
observed from experimental data. Paired and unpaired
Student’s t-test were used for statistical comparisons of in
vivo and in vitro studies, respectively, taking p < 0.05 as
significant.

IV. Blood Collection

V. Determination of Cyclosporin Concentration in
Blood(19,20)
Blood sample (150 µL) was treated with 50 µL of
Solubilization Reagent and 300 µL of Whole Blood
Precipitation Reagent. After well mix, the mixture was
centrifuged at 9,860×g for 5 min to obtain supernatant.
Cyclosporin concentration was then measured by a specific
monoclonal fluorescence polarization immunoassay.
Validation of the calibration curve was carried out by
testing three controls with concentrations of 150.0, 400.0
and 800.0 ng/mL right before sample assay. The assay
was calibrated for concentrations from 25.0 to 1500.0

Figures 1 and 2 depict the blood profiles of
cyclosporin after oral administration of cyclosporin and
coadministration with CS concomitantly and 1 hr before
Concentration of cyclosporin (ng/mL)

Blood samples (0.3 mL) were withdrawn via cardiopuncture at 20, 40, 60, 180, 300 and 540 min after oral
administration and at 5, 10, 20, 40, 60, 180, 300 and 540
min after intravenous bolus. The blood samples were
collected in vacutainer tubes containing 8.55 mg of EDTA
(Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed
within 24 hr.

RESULTS
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Figure 1. Mean (± S.E.) blood concentration - time profiles of
cyclosporin after oral administration of cyclosporin (2.5 mg/kg) ()
and coadministration with 2.0 g/kg cordyceps () in 6 rats.
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superposable and the pharmacokinetic parameters were not
significantly different between the two treatments.
The results of everted intestine sac study are shown in
Figure 4. CS did not significantly alter the efflux transport
of rhodamine 123 from serosal to mucosal side for both
jejunum and ileum.
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Figure 2. Mean (± S.E.) blood concentration - time profiles of
cyclosporin after oral administration of cyclosporin (2.5 mg/kg) ()
and coadministration with 2.0 g/kg cordyceps 1 hr before cyclosporin
() in 7 rats.
Table 1. Pharmacokinetic parameters of cyclosporin in rats after
giving oral cyclosporin (CsA, 2.5 mg/kg) and coadministration with
cordyceps (CS, 2.0 g/kg) (n = 6)
Parameters
CsA
CsA + CS Difference (%)
491.0 ± 100.7 85.9 ± 44.1 -85.5 ± 5.0e
Cmaxa (ng/mL)
Tmaxb (min)
36.7 ± 6.2
50.0 ± 6.8
58.3 ± 35.2e
t1/2c (min)
155.7 ± 29.9 194.8 ± 111.7 20.2 ± 21.9e
AUC0-540d (µg•min/mL) 106.9 ± 29.0
24.4 ± 15.5 -83.2 ± 8.4e
Data expressed as Mean ± S.E.
a
Concentration of peak blood level.
b
Time of peak blood level.
c
Half life.
d
Area under serum concentration - time curve to the last point.
e
p < 0.01 compared with CsA.
Table 2. Pharmacokinetic parameters of cyclosporin in rats after
giving oral cyclosporin (CsA, 2.5 mg/kg) and predosing with
cordyceps 1 hr before cyclosporin (CS 1hr, 2.0 g/kg) (n = 7)
Parameters
CsA
CsA + CS 1hr Difference (%)
Cmax (ng/mL)
952.9 ± 107.8 140.5 ± 44.4 -85.9 ± 4.1a
Tmax (min)
40.0 ± 0.0
57.1 ± 20.7
42.9 ± 51.7
324.5 ± 98.3 293.0 ± 101.5 -5.3 ± 14.1
t1/2 (min)
AUC0-540 (µg•min/mL) 270.2 ± 44.8
44.2 ± 12.8 -84.4 ± 3.7b
Data expressed as Mean ± S.E.
a
p < 0.001 compared with CsA.
b
p < 0.01 compared with CsA.
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Figure 3. Mean (± S.E.) blood concentration - time profiles of
cyclosporin after intravenous bolus of cyclosporin (0.8 mg/kg) ()
and coadministration with 2.0 g/kg () cordyceps in 8 rats.
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cyclosporin.
The pharmacokinetic parameters of
cyclosporin for various treatments are given in Tables 1 and
2. The results showed that coadministration of CS concomitantly and 1 hr before cyclosporin significantly
decreased Cmax of cyclosporin by 85.5% and 85.9%, as well
as reduced AUC0-540 by 83.2% and 84.4%, respectively.
Concomitant administration of CS significantly delayed the
Tmax by 58.3%, whereas coadministration of CS 1 hr before
cyclosporin did not affect Tmax.
Figure 3 depicts the blood profiles of cyclosporin after
intravenous bolus of cyclosporin and coadministration with
CS. The result showed that the two profiles were largely
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Figure 4. Mean (± S.E.) transport of rhodamine 123 from serosal to
mucosal surfaces across the everted jejunum (upper) and ileum
(lower) in the absence (control) () or presence of 0.5 g/beaker of CS
() (n = 3).
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DISCUSSION
Due to the variation of cyclosporin absorption among
individuals, crossover design was conducted in this study
to overcome the great inter-subject difference. This rat
model for herb - cyclosporin interaction had been verified
by a study of coadministration with St. John’s wort and
cyclosporin(22), demonstrating a result in good agreement
with clinical findings(23). In this study, the results indicated
that coadministration of CS markedly reduced the Cmax and
AUC0-540 of oral cyclosporin, whereas the pharmacokinetics of intravenous cyclosporin were not significantly
affected. Apparently, CS markedly decreased the systemic
exposure of oral cyclosporin, but conferred no impact on
the distribution and elimination of intravenous cyclosporin.
Therefore, it can be proposed that CS did not significantly
affect the disposition of cyclosporin and thus the interaction should occur during the absorption phase in gastrointestinal tract (24) . When CS was given 1 hr before
cyclosporin dosing, the Cmax and AUC0-540 of cyclosporin
significantly decreased in no lesser extent than when CS
was coadministered concomitantly, suggesting that direct
pharmaceutical interaction between CS and cyclosporin
could be excluded.
Cyclosporin is a substrate of Pgp, an efflux transporter(25) which is present in intestine and plays as biochemical barrier of drug absorption(26). The results of
everted gut sac study showed that CS did not alter the
function of intestinal Pgp, suggesting that the reduced
cyclosporin bioavailability caused by CS cannot be
explained by the modulation on intestinal Pgp. Since
complex mechanisms of drug absorption were gradually
recognized in recent decades, the interaction mechanism
between CS and cyclosporin might involve metabolizing
enzymes such as CYP3A4 or other ATP-binding cassette
(ABC) transporters beside Pgp.
A previous study reported that CS extract inhibited the
proliferation and IL-2 production of phytohemagglutininstimulated peripheral blood mononuclear cell(13) .
Pharmacodynamically, CS and cyclosporin may cause synergistic effect on immunosupression. However, CS coadministration dramatically inhibited the oral bioavailability
of cyclosporin and resulted in reduced blood level.
Therefore, optimizing the dosage regimen of cyclosporin
requires not only the blood levels of cyclosporin, but also
the pharmacodynamic interaction between CS and
cyclosporin.
In conclusion, cordyceps significantly reduced
cyclosporin bioavailability. Concurrent use of cordyceps
with cyclosporin is better avoided to ensure the efficacy and
safety of cyclosporin.
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